Design and evaluation of bilayer floating tablets of captopril

Acta Pharmaceutica

Volumn 56, Issue 1, 2006, Pages 49-57

  Rahman, Ziyaur ^a   Ali, Mushir ^a   Khar, Rk ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Bilayer floating tablet; Higuchi; HPLC; X ray

Indexed keywords

BICARBONATE; CAPTOPRIL; CARBOMER; CITRIC ACID; HPMC; K15M; PLACEBO; POLYMER; POVIDONE K30; UNCLASSIFIED DRUG;

ARTICLE; BILAYER FLOATING TABLET; CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG MIXTURE; DRUG RELEASE; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; EFFERVESCENT TABLET; HUMAN; STOMACH JUICE; TABLET; TABLET FORMULATION; X RAY ANALYSIS;

EID: 32844470109     PISSN: 13300075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. P. R. Sheth and J. L. Tossounian, The hydrodynamic balanced system (HBS): A novel drug delivery system for oral use, Drug Dev. Ind. Pharm. 10 (1984) 313-339.
2. Y. E. Chien, Potential developments, new approaches in oral controlled release drug delivery systems, Drug Dev. Ind. Pharm. 9 (1993) 486-488.
3. A. A. Deshpande, C. T. Rhodes, N. H. Shah and A. W. Malick, Controlled release drug delivery systems for prolonged gastric residence: an overview, Drug Dev. Ind. Pharm. 22 (1996) 531-539.
4. N. Uzdemir, S. Ordu and Y. Ozkan, Studies of floating dosage forms of furosemide: in vitro and in vivo evaluation of bilayer tablet formulations, Drug Dev. Ind. Pharm. 26 (2000) 857-866.
5. H. M. Ingani, J. Timmermans and A. J. Moes, Conception and in vivo investigation of peroral sustained release floating dosage forms with enhanced gastrointestinal transit, Int. J. Pharm. 35 (1987) 157-164.
6. C. Dollery, Therapeutics Drugs, Churchill Livingstone, New York 1999, pp. c38-c43.
7. N. H. Anaizi and C. Swenson, Instability of captopril solution, Am. J. Hosp. Pharm. 50 (1993) 486-488.
8. Y. Seta, Y. Kawahara, K. Nishimura and R. Okada, Design and preparation of captopril sustained release dosage forms and their biopharmaceutical properties, Int. J. Pharm. 41 (1988) 245-254.
9. A. O. Nur and J. S. Zhang, Captopril floating and/or bioadhesive tablets: design and release kinetics, Drug Dev. Ind. Pharm. 26 (2000) 965-969.
10. United States Pharmacopoeia 23, US Pharmacopoeial Convention, Rockville 1993, p. 951.
11. W. L. Hayton and T. Chen, Correction of perfusate for sample removal, J. Pharm. Sci. 71 (1982) 820-821.
12. F. Barbeto, S. Morrica and F. Quaglia, Analysis of ACE inhibitor by high performance liquid chromatography, Farmaco 49 (1994) 457-460.
13. B. R. Mathews, Regulatory aspects of stability testing in Europe, Drug Dev. Ind. Pharm. 25 (1999) 831-856.
14. D. Lemoine, F. Wauters, S. Bouchend and V. Preat, Preparation and characterization of alginate microspheres containing model antigen, J. Pharam. Sci. 176 (1998) 9-19.
15. Y. Seta, F. Higuchi, T. Otsuka, K. Nishimura, R. Okada and H. Koike, Preparation and pharmacological evaluation of captopril sustained release dosage forms using oily semisolid matrix, Int. J. Pharm. 41 (1988) 255-262.
16. J. G. Wagner, Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules, J. Pharm. Sci. 58 (1969) 1253-1257.
17. T. Higuchi, Mechanism of sustained action medication, J. Pharm. Sci. 52 (1963) 1145-1149.
18. R. W. Korsmeyer, R. Gurny, E. Doelker, P. Buri and N. A. Peppas, Mechanism of solute release from hydrophilic polymers, Int. J. Pharm. 15 (1983) 25-35.
19. N. A. Peppas, Analysis of Fickian and non Fickian drug release from polymers, Pharm. Acta Helv. 60 (1985) 110-111.
20. P. Costa and J. S. M. S. Labo, Modelling and comparison of dissolution profiles, Eur. J. Pharm. Sci. 13 (2001) 123-133.